참고문헌
- Bang YJ, Van Cutsem E, Feyereislova A, et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 28, 687-97
- Bardin C, Astier A, Vulto A, et al (2011). Guidelines for the practical stability studies of anticancer drugs: a European consensus conference. Ann Pharm Fr, 69, 221-31. https://doi.org/10.1016/j.pharma.2011.07.002
- Cook-Bruns N (2001). Retrospective analysis of the safety of herceptin immunotherapy in metastatic breast cancer. Oncology, 61, 58-66. https://doi.org/10.1159/000055403
- Halyard MY, Pisansky TM, Dueck AC, et al (2009). Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol, 27, 2638-44. https://doi.org/10.1200/JCO.2008.17.9549
- Lenz HJ (2007). Management and preparedness for infusion and hypersensitivity reactions. The Oncologist, 12, 601-9. https://doi.org/10.1634/theoncologist.12-5-601
- Leyland-Jones B, Gelmon K, Ayoub JP (2003). Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol, 21, 3965-71. https://doi.org/10.1200/JCO.2003.12.109
- Owens MA, Horten BC, Da Silva MM (2004). HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer, 5, 63-9. https://doi.org/10.3816/CBC.2004.n.011
- Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer; correlation of relapse and survival with amplification of the HER2/neu oncogene. Science, 235, 177-82. https://doi.org/10.1126/science.3798106
- Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783-92. https://doi.org/10.1056/NEJM200103153441101
- Slamon D, Eiermann W, Robert N, et al (2011). Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med, 365, 1273-83. https://doi.org/10.1056/NEJMoa0910383
- Suter TM, Procter M, van Veldhuisen DJ, et al (2007). Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol, 25, 3859-65. https://doi.org/10.1200/JCO.2006.09.1611
- Tan-Chiu E, Yothers G, Romond E, et al (2005). Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol, 23, 7811-9. https://doi.org/10.1200/JCO.2005.02.4091
- Trotti A, Colevas AD, Setser A, et al (2003). CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 13, 176-81 https://doi.org/10.1016/S1053-4296(03)00031-6
피인용 문헌
- Patients with HER2-positive Early Breast Cancer Receiving Adjuvant Trastuzumab: Clinicopathological Features, Efficacy, and Factors Affecting Survival vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1643